Corient Capital Partners’s Zoetis ZTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$3.84M Buy
22,340
+108
+0.5% +$18.1K 0.29% 81
2022
Q2
$3.82M Buy
22,232
+3,211
+17% +$555K 0.29% 86
2022
Q1
$3.59M Buy
19,021
+26
+0.1% +$5.14K 0.24% 95
2021
Q4
$4.63M Buy
18,995
+195
+1% +$42.7K 0.31% 82
2021
Q3
$3.65M Buy
18,800
+458
+2% +$92.4K 0.27% 87
2021
Q2
$3.42M Buy
18,342
+1,755
+11% +$305K 0.25% 86
2021
Q1
$2.61M Buy
16,587
+1,378
+9% +$218K 0.22% 93
2020
Q4
$2.52M Buy
15,209
+719
+5% +$117K 0.25% 87
2020
Q3
$2.4M Sell
14,490
-278
-2% -$42.7K 0.28% 86
2020
Q2
$2.02M Buy
14,768
+2,684
+22% +$350K 0.25% 94
2020
Q1
$1.42M Buy
12,084
+3,907
+48% +$514K 0.22% 99
2019
Q4
$1.08M Sell
8,177
-942
-10% -$117K 0.14% 161
2019
Q3
$1.14M Buy
9,119
+3,625
+66% +$438K 0.16% 148
2019
Q2
$624K Buy
5,494
+1,322
+32% +$138K 0.1% 205
2019
Q1
$420K Buy
4,172
+772
+23% +$70.1K 0.07% 246
2018
Q4
$290K Buy
+3,400
New +$306K 0.05% 264

Other funds holding ZTS

Corient Capital Partners's ZTS Position: Q3 2022 in Review

Corient Capital Partners increased its Zoetis (ZTS) stake by 0.49% in Q3 2022, buying an estimated $18.1K and bringing the position to 22,340 shares worth $3.84M. The position accounts for 0.29% of the portfolio, ranked #81.

Corient Capital Partners first reported a position in ZTS in Q4 2018 and has held it in 16 quarters since. The position peaked at $4.63M in Q4 2021. 1,508 funds tracked by Wall St. Rank hold ZTS as of Q3 2022.

  • Corient Capital Partners held 22,340 shares of Zoetis worth $3.84M as of Q3 2022.
  • Corient Capital Partners bought 108 Zoetis shares in Q3 2022, an estimated $18.1K.
  • Zoetis made up 0.29% of Corient Capital Partners's portfolio in Q3 2022, its #81 holding.
  • Corient Capital Partners first reported a position in Zoetis in Q4 2018 and has held it in 16 quarters since.
  • Corient Capital Partners's Zoetis position peaked at $4.63M in Q4 2021.
  • 1,508 funds tracked by Wall St. Rank held Zoetis as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.